Description:
Project ID: D2019-30
Background:
With an estimated 6.3 million bone related injuries in the US, the cost for treating has skyrocketed. While autograft methods are associated with morbidity and pain along with high resorption rate, allograft methods are prone to a high risk of disease transmission and immunogenic rejection. Thus, there is an increasing demand for alternative methods to bone graft techniques to combat bone related injuries. Alternative techniques based on tissue scaffolds that can effectively combine key components of bone tissue engineering such as osteogenic progenitor cells, osteoinductive factors, and osteoconductive materials is gaining much interest in the area of bone regeneration. Hence, it is advantageous to develop a new and improved compositions and the need for injectable scaffolds that can undergo a sol-gel transition at physiological conditions is vital.
Invention Description:
Researchers at the University of Toledo, have developed a novel multicomponent releasing microparticle (MP) gel scaffolds to facilitate BMP-9 induced bone formation at a low dose. The thermosensitive gel is an injectable medium for BMP-9 coated MPs so that their injectability property could be preserved while also increasing the efficacy of BMP-9 at the injection site through the localization of MPs. BMP-9 coated on the MPs and VEGF introduced to the thermosensitive gel were both bioactive and their temporal release profile enabled improved osteogenic responses. The MPs-gel with BMP-9 and VEGF were found to enhance both subcutaneous and cranial bone formation, indicated by significantly higher bone formation induced by MPs-gel+V+B group. Taken together, the BMP-9 combined with VEGF when delivered through injectable microparticles-gel composites enhance the bone formation at a low dose of BMP-9.
Applications:
Bone regeneration
Advantages:
• Use of minimally invasive techniques to administer at local site. Thus, reducing surgery time and cost.
• Delivery of low doses of BMP-9 and VEGF over time.
• Doses can be controlled over time with the specific application.
• Harden at physiological temperature.
• Bone formation with BMP-9 is not as vigorous as BMP-2.
• No abnormal bone growth observed in pre-clinical studies with BMP-9.
• Can be manipulated to use in other drug delivery applications.
• All the materials are biocompatible and biodegradable.
IP Status: US Patent 11241504
Publications: C. Jayasuriya, Ambalangodage, et al. “Thermoresponsive Injectable Microparticle–Gel Composites with Recombinant BMP-9 and VEGF Enhance Bone Formation in Rats.” ACS Biomaterials Science & Engineering, pubs.acs.org/doi/abs/10.1021/acsbiomaterials.9b00082.